Subscribe to Learn More
BARDA, Department of Defense, and SAb Biotherapeutics to Partner to Develop a Novel COVID-19 Therapeutic
April 6, 2020 by Admin
Published by Medical Counter Measures
A therapeutic to treat novel coronavirus disease 2019 (COVID-19) is moving forward in development through a partnership between BARDA, the Department of Defense Joint Program Executive Office for Chemical, Biological, Radiological, and Nuclear Defense (JPEO – CBRND), and SAb Biotherapeutics, Inc. (SAb), of Sioux Falls, South Dakota.
Using an interagency agreement with JPEO’s Medical CBRN Defense Consortium, BARDA transferred approximately $7.2 million in funding to (JPEO – CBRND) to support SAb to complete manufacturing and preclinical studies, with an option to conduct a Phase 1 clinical trial.
Agri-Pulse: Can cows be used to fight coronavirus?
March 30, 2020 by Admin
Bovine plasma donors genetically engineered to produce human antibodies are in the front lines of the struggle against coronavirus.
SAB Biotherapeutics, a Sioux Falls, S.D., biotechnology company that has been successfully testing use of antibodies from cows to fight diseases such as another coronavirus, Middle East respiratory syndrome, now is engaged in developing a treatment for COVID-19, the disease caused by the novel coronavirus.
Times Argus: High-tech chestnuts: US to consider genetically altered tree
November 7, 2019 by Admin
SYRACUSE, N.Y. (AP) — Chestnuts harvested from high branches on a chilly fall morning look typical: they’re marble sized, russet colored and nestled in prickly burs. But many are like no other nuts in nature.
In a feat of genetic engineering, about half the chestnuts collected at this college experiment station feature a gene that provides resistance to blight that virtually wiped out the American chestnut tree generations ago.